- Barrons.com•8 hours ago
Maxim Group A seemingly benign, and to us an expected event from Shire, could translate into two very different outcomes for Coherus BioSciences and Momenta Pharmaceuticals. Both Coherus and Momenta announced that Shire (SHPG) has returned rights to each of their anti-TNF biosimilars: Coherus’ CHS-0214 (Enbrel) and Momenta’s M923 (Humira). The announcement was not a complete surprise as Shire had openly discussed the potential of not developing biosimilars that came on board as a result of the acquisition of Baxalta.
- GlobeNewswire•2 days ago
REDWOOD CITY, Calif., Sept. 27, 2016-- Coherus BioSciences, Inc. today announced that it has regained from Shire plc all development and commercial rights previously licensed for CHS-0214 etanercept, a ...
Coherus Biosciences, Inc. (CHRS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||18.00 x 100|
|Ask||30.95 x 100|
|Day's Range||28.75 - 31.16|
|52wk Range||12.04 - 31.98|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.37|
|Avg Vol (3m)||396,356|
|Dividend & Yield||N/A (N/A)|